Results 161 to 170 of about 2,183,179 (300)
Control of Schwann Cell Myelination by DDR1 Receptor Tyrosine Kinase. [PDF]
Fan M +6 more
europepmc +1 more source
Sarbecovirus ORF9b recruits host phosphatase PPM1A to suppress innate immunity through dual mechanisms. PPM1A directly dephosphorylates ORF9b to sustain its activity and indirectly downregulates STAT2 phosphorylation to impair interferon signaling. Pharmacological inhibition of PPM1A restores antiviral responses and limits sarbecovirus replication ...
Lixiang Xie +24 more
wiley +1 more source
A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes
Laura Schubert +7 more
doaj +1 more source
PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. [PDF]
Fearon AE +18 more
europepmc +1 more source
Drug Repurposing for Treating NCOR‐Related Intellectual Disability
An autism‐associated NCOR1 heterozygous mutation upregulates NRGs and activates NRG backward signaling in hypothalamic GABAergic neurons in mouse models, leading to Gabra2 downregulation and cognitive deficits, which can be therapeutically targeted by repurposing FDA‐approved drugs.
Yan Kong +15 more
wiley +1 more source
Regulation of oestrogen signalling by the receptor tyrosine kinase cKIT stabilises Barrett's oesophagus pre-malignant state. [PDF]
Suen KM +5 more
europepmc +1 more source
An advanced, long‐term human skin platform maintains native skin structure and key tissue functions for up to four weeks. The platform models chronic inflammation, aging‐related skin changes, and UVB damage, enabling drug and topical interventions—including anti‐inflammatory therapy, senolytic treatment, and sunscreen—to be evaluated in intact human ...
Purnendu Kumar Sharma +14 more
wiley +1 more source
Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass. [PDF]
Ahmad M +13 more
europepmc +1 more source
A large‐scale multicenter serum metabolomics study (13 centers, n = 2,149) identified a 9‐metabolite + AFP diagnostic signature for liver cancer (AUC = 0.93). Among the signature, nicotinamide (NAM) was validated as an oncometabolite: NAM enhances NAD+ synthesis, activating SIRT1 to deacetylate and stabilize HIF1α, thereby driving glycolysis, MAPK ...
Yongjie Xu +13 more
wiley +1 more source
MACC1 Hyperactivates Receptor Tyrosine Kinase Signaling Through Phosphorylation-Dependent Adaptor Activity in Colorectal Cancer Cells. [PDF]
Zincke F +8 more
europepmc +1 more source

